Intrinsiqq

Navamedic ASA (NAVA.XOSL) Quality Score

NAVA.XOSL
Quality27

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-25.0x

Negative earnings, no valuation support

Cash Flow Multiple
80/100
23.2x

20–25x, moderate cash flow premium

Revenue Growth
100/100
11.0%

Above 10% CAGR, strong compounder

Cash Flow Growth
0/100
-3.5%

Below 2%, essentially flat

Business Quality & Capital Allocation

Share Dilution
0/100
40.4%

Heavy dilution above 5%

Margin Trend
0/100
-9.6pp

Contracted >2pp, margin pressure

Capital Structure
0/100
kr 145M

Net debt/FCF of 10.7x, high leverage

2022
kr 64M
kr 63M
2023
kr 38M
kr 174M
2024
kr 52M
kr 140M
2025
kr 82M
kr 227M
Return on Capital
0/100
2.8%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Navamedic ASA (NAVA.XOSL) quality: score, margins and returns

Navamedic ASA (NAVA.XOSL) scores 27/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 7 metrics each scored 0 to 100, on 2.1% operating margins and 2.8% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Navamedic ASA (NAVA.XOSL) a high-quality business?+

Navamedic ASA scores 27 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a 2.1% operating margin and a 2.8% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Navamedic ASA's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from NAVA.XOSL's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Navamedic ASA scores well and where it falls behind.

What is Navamedic ASA's return on invested capital (ROIC)?+

Navamedic ASA earns about 2.8% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to NAVA.XOSL's margins and growth on this scorecard to judge durability.

How profitable is Navamedic ASA?+

Navamedic ASA runs an operating margin of about 2.1% and a net margin of about -0.8%. Revenue has grown at roughly 19.4% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on NAVA.XOSL: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Related stocks: Medical Distribution

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.